BWAY (61) SSII (39) DCTH (57) SENS (38) ⌘ Pro Terminal →

Cerus Corporation (CERS) — RQD Stock Rating Cockpit

$2.44 +0.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cerus Corporation (CERS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $491.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CERS)Realized 20D OHLCV Swing Band: ±8.5%

RSI-14 MOMENTUMNEUTRAL RANGE

4330 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE51% OF RANGE

L: $1$2.44H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CERS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-15.5% ROIC with 42.0% gross margin and 0.23% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like CERS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CERS)

✓Walkthrough of CERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.20%⚡ TESTING RESISTANCE

2026-10-30O $2.41H $2.44L $2.25C $2.44VOL 1.50M

RES: $2.47SUP: $2.13SMA50: $2.47SMA200: $2.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CERS Butterfly Map → + Track CERS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CERS)

Health Care Rank #746 of 1016 ⚔️ BWAY vs CERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CERS vs. BWAY, SSII, DCTH, SENS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cerus Corporation (CERS) ranks #746 by composite RQD confidence (37/100, grade D-) and #456 by equity capitalization ($491.7M). Within this direct 5-issuer industry benchmark cohort, CERS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. BWAY currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CERS at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CERS ACTIVE Cerus Corporation	D-	37/100	—	—	-15.5%	+0.83%	$491.7M	Benchmark Subject
BWAY BrainsWay Ltd.	C-	61/100	—	—	—	+4.93%	$478.7M	/bway-vs-cers →
SSII SS Innovations International Inc.	D-	39/100	—	46.0%	-18.5%	-2.46%	$477.2M	/ssii-vs-cers →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-cers →
SENS Senseonics Holdings Inc.	D-	38/100	—	44.7%	-35.0%	+4.39%	$515.5M	/sens-vs-cers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001020214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerus Corporation (CERS) reported GAAP revenue of $233.8M (+16.1% vs. FY2024 revenue of $201.3M , and +25.2% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of $4.8M, and free cash flow of $1.1M (-87.0% YoY). On the balance sheet, CERS closed FY2025 with $221.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$233.8M	-$15.6M	$4.8M	$1.1M	$221.9M	—
FY2024 (FY)	2024-12-31	$201.3M	-$20.9M	$11.4M	$8.5M	$200.9M	—
FY2023 (FY)	2023-12-31	$186.8M	-$37.5M	-$43.2M	-$43.2M	—	—

3. CERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cerus Corporation (NASDAQ: CERS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.44 (+0.83% 1D, market cap $491.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #746 in composite RQD confidence.

How does CERS compare to BWAY and SSII in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $478.7M) and SSII (SS Innovations International Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CERS?

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CERS trading relative to its 50-day, 200-day, and 52-week technical levels?

CERS last traded at $2.44 (+0.83% on volume of 1,353,272 shares), positioning the stock -1.21% below its 50-day simple moving average ($2.47) and -0.41% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.38 to $3.47, CERS sits at the 50.7% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($2.23 to $2.65).

CERS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CERS stock right now?

Cerus Corporation (CERS) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.

What is CERS's 12-month price target and RQD AI Jury consensus?

CERS's 12-month base price target is $2.21 (range $1.72 to $3.64), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CERS RQD Cockpit CERS 12M Forecast CERS Earnings & Move CERS Dividends & DRIP CERS Insiders & 13F CERS Whale Options CERS Profit Sankey CERS News & Why